Compare Stocks

→ Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$133.46 +0.2%	$145.26	$83.75 ▼ $161.00	$7.77B	0.54	364,990 shs	210,512 shs
AVL Avalon Advanced Materials	C$0.07	C$0.08	C$0.06 ▼ C$0.18	C$36.72M	1.17	132,376 shs	26,050 shs
GSP iPath S&P GSCI Total Return Index ETN	$19.66	$19.65	$18.19 ▼ $28.75	$21.84M	N/A	3,679 shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-0.60%	-5.65%	-13.37%	-6.08%	+36.07%
AVL Avalon Advanced Materials	-7.14%	-7.14%	-13.33%	-23.53%	-40.91%
GSP iPath S&P GSCI Total Return Index ETN	0.00%	0.00%	0.00%	0.00%	+0.28%

Biggest hedge fund manager has huge warning for U.S. dollar (Ad)

Prescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."

Get the details before it's taken offline.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASND Ascendis Pharma A/S	1.1553 of 5 stars	3.4	0.0	0.0	0.0	1.9	1.7	0.6
AVL Avalon Advanced Materials	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GSP iPath S&P GSCI Total Return Index ETN	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	2.88	Moderate Buy	$173.88	30.28% Upside
AVL Avalon Advanced Materials	N/A	N/A	N/A	N/A
GSP iPath S&P GSCI Total Return Index ETN	0.00	N/A	N/A	N/A

Current Analyst Ratings

Latest AVL, GSP, ASND, S2R, and MGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/3/2024	ASND Ascendis Pharma A/S	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$260.00 ➝ $262.00
5/3/2024	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$173.00
5/3/2024	ASND Ascendis Pharma A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$167.00 ➝ $170.00
4/22/2024	ASND Ascendis Pharma A/S	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$116.00 ➝ $116.00
4/18/2024	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$173.00
4/2/2024	ASND Ascendis Pharma A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$165.00 ➝ $167.00
4/1/2024	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$173.00
3/15/2024	ASND Ascendis Pharma A/S	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$196.00 ➝ $260.00

(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$329.02M	23.62	N/A	N/A	($2.73) per share	-48.89
AVL Avalon Advanced Materials	C$21.77K	1,686.79	C$0.00 per share	17.14	C$0.23 per share	0.28
GSP iPath S&P GSCI Total Return Index ETN	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$521.07M	-$9.61	N/A	N/A	N/A	-152.68%	-16,574.15%	-60.06%	9/3/2024 (Estimated)
AVL Avalon Advanced Materials	C$1.09M	-C$0.01	N/A	∞	N/A	345.06%	0.28%	-2.66%	7/2/2024 (Estimated)
GSP iPath S&P GSCI Total Return Index ETN	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
AVL Avalon Advanced Materials	N/A	N/A	N/A	N/A	N/A
GSP iPath S&P GSCI Total Return Index ETN	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	N/A	0.83	0.54
AVL Avalon Advanced Materials	3.12	0.50	2.13
GSP iPath S&P GSCI Total Return Index ETN	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
AVL Avalon Advanced Materials	N/A
GSP iPath S&P GSCI Total Return Index ETN	N/A

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
AVL Avalon Advanced Materials	21.47%
GSP iPath S&P GSCI Total Return Index ETN	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	879	58.22 million	34.93 million	Optionable
AVL Avalon Advanced Materials	9	564.84 million	N/A	Not Optionable
GSP iPath S&P GSCI Total Return Index ETN	2,020	1.11 million	N/A	Not Optionable

AVL, GSP, ASND, S2R, and MGL Headlines

Source	Headline
	iPath S&P GSCI Total Return Index ETN (NYSEARCA:GSP) Share Price Passes Above 50-Day Moving Average of $19.65 americanbankingnews.com - May 1 at 4:08 AM
	Here Are 2 Remarkable Growth Stocks to Own Right Now theglobeandmail.com - March 29 at 3:08 PM
	SPGSHO S&P GSCI Heating Oil Index Spot seekingalpha.com - December 28 at 11:36 PM
	SGECASP S&P GSCI Agriculture Enhanced Select Index Spot Excess Return seekingalpha.com - November 22 at 11:11 PM
	2023 ETF Stock Price History investing.com - November 18 at 7:19 PM
	GSP ETF Stock Price History investing.com - November 18 at 7:19 PM
	OBX Uncapped Total Return (OBXU) uk.investing.com - October 9 at 11:17 PM
	S&P-GSCI Excess Return Index Jan 2024 barrons.com - September 25 at 12:08 AM
	SP500-5510TR S&P 500 Utilities Index Industry Group - Total Return seekingalpha.com - September 14 at 4:48 AM
	iPath S&P GSCI Crude Oil Total Return investing.com - September 3 at 6:14 PM
	SPGSPAP S&P GSCI Palladium Index Excess Return seekingalpha.com - August 26 at 5:30 PM
	Fed's 2022 rate hikes haven't 'fully worked itself into the system': Strategist finance.yahoo.com - July 25 at 2:20 PM
	S&P GSCI Crude Oil Index Excess Return (SPGSCLP) investing.com - October 16 at 12:13 PM
	S&P-GSCI Excess Return Index Dec 2022 marketwatch.com - October 14 at 10:46 AM
	COW iPath DJ-UBS Livestock Total Return Sub-Index ETN seekingalpha.com - September 23 at 8:21 AM
	Inflation: Unpacking the numbers in the latest Consumer Price Index report finance.yahoo.com - December 10 at 6:10 PM
	Anita Hill on ending gender violence: we need to ‘challenge the system’ finance.yahoo.com - October 19 at 7:58 PM
	Medicare in peril as funding runs low finance.yahoo.com - September 1 at 3:55 PM
	Morning Brief: Data suggest retail sales slumped last month finance.yahoo.com - August 13 at 4:40 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ascendis Pharma A/S

NASDAQ:ASND

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Avalon Advanced Materials

TSE:AVL

Avalon Advanced Materials Inc., together with its subsidiaries, engages in the acquisition, exploration, evaluation, and development of rare metal and mineral properties primarily in Canada. The company focuses on exploring lithium, tantalum, cesium, indium, gallium, germanium, tin, yttrium, and zirconium deposits, as well as rare earth elements. Its flagship project is the 100% owned Separation Rapids Lithium Project consisting of nineteen mineral claims and one mining lease covering an area of approximately 4,414 hectares located in the Paterson Lake Area, Kenora Mining Division, Ontario. The company was formerly known as Avalon Rare Metals Inc. and changed its name to Avalon Advanced Materials Inc. in February 2016. Avalon Advanced Materials Inc. is headquartered in Toronto, Canada.

iPath S&P GSCI Total Return Index ETN

NYSEARCA:GSP

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial